A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses …

L Du, Z Kou, C Ma, X Tao, L Wang, G Zhao, Y Chen… - PloS one, 2013 - journals.plos.org
An emerging respiratory infectious disease with high mortality, Middle East respiratory
syndrome (MERS), is caused by a novel coronavirus (MERS-CoV). It was first reported in …

A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein

Y Chen, S Lu, H Jia, Y Deng, J Zhou… - Emerging microbes & …, 2017 - Taylor & Francis
Middle East respiratory syndrome coronavirus (MERS-CoV) has caused fatal infections,
some through hospital-acquired transmission, in affected regions since its emergence in …

MERS-CoV spike protein: targets for vaccines and therapeutics

Q Wang, G Wong, G Lu, J Yan, GF Gao - Antiviral research, 2016 - Elsevier
The disease outbreak caused by Middle East respiratory syndrome coronavirus (MERS-
CoV) is still ongoing in the Middle East. Over 1700 people have been infected since it was …

Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein

L Jiang, N Wang, T Zuo, X Shi, KMV Poon… - Science translational …, 2014 - science.org
The recently identified Middle East respiratory syndrome coronavirus (MERS-CoV) causes
severe and fatal acute respiratory illness in humans. However, no prophylactic and …

A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein

Y Li, Y Wan, P Liu, J Zhao, G Lu, J Qi, Q Wang, X Lu… - Cell research, 2015 - nature.com
Abstract The newly-emerging Middle East respiratory syndrome coronavirus (MERS-CoV)
can cause severe and fatal acute respiratory disease in humans. Despite global efforts, the …

Advances in MERS-CoV vaccines and therapeutics based on the receptor-binding domain

Y Zhou, Y Yang, J Huang, S Jiang, L Du - Viruses, 2019 - mdpi.com
Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) is an infectious virus
that was first reported in 2012. The MERS-CoV genome encodes four major structural …

Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus

J Tang, N Zhang, X Tao, G Zhao, Y Guo… - Human vaccines & …, 2015 - Taylor & Francis
Middle East respiratory syndrome (MERS) is an emerging infectious disease caused by
MERS coronavirus (MERS-CoV). The continuous increase of MERS cases has posed a …

A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike …

L Du, G Zhao, Y Yang, H Qiu, L Wang, Z Kou… - Journal of …, 2014 - Am Soc Microbiol
Prophylactic and therapeutic strategies are urgently needed to combat infections caused by
the newly emerged Middle East respiratory syndrome coronavirus (MERS-CoV). Here, we …

Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27

X Yu, S Zhang, L Jiang, Y Cui, D Li, D Wang, N Wang… - Scientific reports, 2015 - nature.com
Abstract The recently reported Middle East respiratory syndrome coronavirus (MERS-CoV)
causes severe respiratory illness in humans with an approximately 30% mortality rate. The …

[HTML][HTML] A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV …

W Tai, G Zhao, S Sun, Y Guo, Y Wang, X Tao… - Virology, 2016 - Elsevier
Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) was first identified in
2012, and it continues to threaten human health worldwide. No MERS vaccines are licensed …